THERAPY DOSSIER · th-1851c162710a

PAR2 antagonistic peptide and the adenylyl cyclase inhibitor SQ22536

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Crush
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22541444 ↗2012Mixed findings

Chronic compression or acute dissociation of dorsal root ganglion induces cAMP-dependent neuronal hyperexcitability through activation of PAR2.

RatCrushPeripheral-nerve crushSprague-DawleyMalePAR2 antagonistic peptide applied before and during injury; SQ22536 administere…

Model: Chronic compression of the dorsal root ganglion (CCD) and acute dissociation of dorsal root ganglion neurons

Pretreatment with the PAR2 antagonistic peptide prevented the increases in cAMP and PKA activity, neuronal hyperexcitability and thermal hyperalgesia, but post-treatment did not. SQ22536 given after injury successfully suppressed hyperexcitability and hyperalgesia.

Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…